<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRED MILD- prednisolone acetate suspension/ drops </strong><br>Preferred Pharmaceuticals, Inc<br></p></div>
<h1>PRED MILD<span class="Sup">®</span><br>(prednisolone acetate ophthalmic suspension, USP) 0.12% </h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_047f6756-237b-49c9-91a3-0c630ef0f16d"></a><a name="section-1"></a><p></p>
<p class="First">sterile </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_0ad58c24-f167-4383-8634-b3c522c8ced3"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION </h1>
<p class="First">PRED MILD<span class="Sup">®</span> (prednisolone acetate ophthalmic suspension, USP) 0.12% is a topical anti-inflammatory agent for ophthalmic use. </p>
<p><span class="Bold">Structural Formula:</span></p>
<div class="Figure"><img alt="Structural Formula " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=90fba723-51b1-4404-a30b-816f35001d91&amp;name=90fba723-51b1-4404-a30b-816f35001d91-01.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f68a1744-01e0-47c3-811b-8d48eb613e10"></a><a name="section-2.1"></a><p></p>
<h2>Chemical Name: </h2>
<p class="First">11β, 17, 21-Trihydroxypregna-1, 4-diene-3, 20-dione 21-acetate </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6e5788e0-5bca-4e6c-973b-e133e2310a1b"></a><a name="section-2.2"></a><p></p>
<h2>Contains: </h2>
<p class="First"><span class="Bold">Active:</span> prednisolone acetate (microfine suspension) 0.12%. <span class="Bold">Preservative:</span> benzalkonium chloride. <span class="Bold">Inactives:</span> boric acid; edetate disodium; hypromellose; polysorbate 80; purified water; sodium bisulfite; sodium chloride; and sodium citrate. The pH during its shelf life ranges from 5.0 - 6.0. </p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_65c5e8e2-9d83-420e-97fc-4fa8942bca23"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY </h1>
<p class="First">Prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. Glucocorticoids inhibit the <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as well as capillary proliferation, deposition of collagen, and <span class="product-label-link" type="condition" conceptid="4050007" conceptname="Scar">scar</span> formation. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_86b83b3d-62a4-4275-bfc3-9ea4c9ff1086"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE </h1>
<p class="First">PRED MILD<span class="Sup">®</span> is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">thermal burns</span>). </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_52f5799c-d283-4848-8dd1-bb1cf888e937"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS </h1>
<p class="First">PRED MILD<span class="Sup">®</span> suspension is contraindicated in acute untreated purulent ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, in most viral diseases of the cornea and conjunctiva including epithelial <span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">herpes simplex keratitis</span> (<span class="product-label-link" type="condition" conceptid="373404" conceptname="Ophthalmic herpes simplex">dendritic keratitis</span>), <span class="product-label-link" type="condition" conceptid="140633" conceptname="Vaccinia">vaccinia</span>, and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>, and also in <span class="product-label-link" type="condition" conceptid="4009326" conceptname="Mycobacterial infection">mycobacterial infection</span> of the eye and fungal diseases of ocular structures. PRED MILD<span class="Sup">®</span> suspension is also contraindicated in individuals with known or suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients of this preparation and to other corticosteroids. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_2bc94a6a-2b53-4f2a-9a89-fe38106c756f"></a><a name="section-6"></a><p></p>
<h1>WARNINGS </h1>
<p class="First">Prolonged use of corticosteroids may result in <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with damage to the optic nerve, defects in visual acuity and fields of vision, and in <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation. Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
<p>Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal and <span class="product-label-link" type="condition" conceptid="4088088" conceptname="Scleral thinning">scleral thinning</span>. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. </p>
<p>Acute purulent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the eye may be masked or activity enhanced by the presence of corticosteroid medication. </p>
<p>If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients. Steroids should be used with caution in the presence of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Intraocular pressure should be checked frequently. </p>
<p>The use of steroids after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery may delay healing and increase the incidence of bleb formation. </p>
<p>Use of ocular steroids may prolong the course and may exacerbate the severity of many <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the eye (including herpes simplex). Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution; frequent slit lamp microscopy is recommended. </p>
<p>Corticosteroids are not effective in mustard gas <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> and Sjögren's <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>. </p>
<p>Contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_450c2f04-382e-4f4f-a079-4346922afb47"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS </h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_4876f83e-f109-4e31-996c-47e5b74f5a7f"></a><a name="section-7.1"></a><p></p>
<h2>General: </h2>
<p class="First">The initial prescription and renewal of the medication order beyond 20 milliliters of PRED MILD<span class="Sup">®</span> should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated. </p>
<p>As <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid applications, fungal invasion should be suspected in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where a corticosteroid has been used or is in use. Fungal cultures should be taken when appropriate. </p>
<p>If this product is used for 10 days or longer, intraocular pressure should be monitored (see <span class="Bold"><a href="#i4i_warnings_id_2bc94a6a-2b53-4f2a-9a89-fe38106c756f">WARNINGS</a></span>). </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_c1924cc1-4eab-4e17-914d-005fa6e518df"></a><a name="section-7.2"></a><p></p>
<h2>Information for patients: </h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> persists longer than 48 hours or becomes aggravated, the patient should be advised to discontinue use of the medication and consult a physician. </p>
<p>This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the bottle tip to eyelids or to any other surface. The use of this bottle by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Keep bottle tightly closed when not in use. Keep out of the reach of children. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_38dd8602-83bb-495b-bb9d-2915c5281310"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility: </h2>
<p class="First">No studies have been conducted in animals or in humans to evaluate the potential of these effects. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_4718a2bf-2f42-47c2-89a6-b413ad726b65"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy Category C: </h2>
<p class="First">Prednisolone has been shown to be teratogenic in mice when given in doses 1-10 times the human dose. There are no adequate well-controlled studies in pregnant women. Prednisolone should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p>Dexamethasone, hydrocortisone, and prednisolone were ocularly applied to both eyes of pregnant mice five times per day on days 10 through 13 of gestation. A significant increase in the incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> was observed in the fetuses of the treated mice. </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_94a89367-14a8-4ef9-b34c-c0a199e1542a"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers: </h2>
<p class="First">It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from prednisolone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_61696d2a-2f3a-4c9e-96a3-bcb6d8b2befd"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use: </h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_8fe0fb43-8900-4f04-b28d-26acf5690bdb"></a><a name="section-7.7"></a><p></p>
<h2>Geriatric Use: </h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_f9612909-d2aa-49ed-ac77-1be36f09d991"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS </h1>
<p class="First">Adverse reactions include, in decreasing order of frequency, elevation of intraocular pressure (IOP) with possible development of <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> and infrequent optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataract</span> formation, and delayed <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing. </p>
<p>Although systemic effects are extremely uncommon, there have been rare occurrences of systemic <span class="product-label-link" type="condition" conceptid="195212" conceptname="Hypercortisolism">hypercorticoidism</span> after use of topical steroids. </p>
<p>Corticosteroid-containing preparations have also been reported to cause acute <span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">anterior uveitis</span> and perforation of the globe. <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">Keratitis</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcers</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperemia</span>, loss of accommodation and <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span> have occasionally been reported following local use of corticosteroids. </p>
<p>The development of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (bacterial, fungal, and viral) has occurred. Fungal and <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> of the cornea are particularly prone to develop coincidentally with long-term applications of steroids. The possibility of fungal invasion should be considered in any persistent <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> where steroid treatment has been used (see <span class="Bold"><a href="#i4i_warnings_id_2bc94a6a-2b53-4f2a-9a89-fe38106c756f">WARNINGS</a></span>). </p>
<p>Transient burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> upon instillation and other minor symptoms of ocular irritation have been reported with the use of PRED MILD<span class="Sup">®</span> suspension. </p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_f620de99-3aa4-4b98-be1a-aa2f9977a010"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE </h1>
<p class="First">Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_2784a67b-50e9-4ebd-a34c-594c98c93db7"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION </h1>
<p class="First"><span class="Bold">Shake well before using.</span> Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely. </p>
<p>If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated (see <span class="Bold"><a href="#i4i_precautions_id_450c2f04-382e-4f4f-a079-4346922afb47">PRECAUTIONS</a></span>). </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_cb157aa4-b6f6-4890-9bb4-d85f52ec8b5e"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED </h1>
<p class="First">PRED MILD® (prednisolone acetate ophthalmic suspension, USP) 0.12% is supplied sterile in opaque white LDPE plastic bottles with droppers with white high impact polystyrene (HIPS) caps as follows:</p>
<p>5 mL in 10 mL bottle - NDC 68788-9876-5</p>
<p><span class="Bold">Note:</span> Store at 15° - 30°C (59° - 86°F) in an upright position. Protect from freezing.</p>
<p><span class="Bold">Rx Only</span></p>
<p>Revised June 2004 </p>
<p><span class="Bold">© 2004 Allergan, Inc.</span><br>Irvine, CA 92612, U.S.A. <br>® Marks owned by Allergan, Inc. </p>
<p> 6295X<br>71739US10P </p>
<p>Relabeled By Preferred Pharmaceuticals, Inc</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_9fbcdecc-6bf5-44a1-a3b8-571e83f36508"></a><a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure"><img alt="Pred Mild (Prednisolone Acetate Ophthalmic Suspension, USP 0.12%) label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=90fba723-51b1-4404-a30b-816f35001d91&amp;name=90fba723-51b1-4404-a30b-816f35001d91-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRED MILD 		
					</strong><br><span class="contentTableReg">prednisolone acetate suspension/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68788-9876(NDC:11980-174)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>prednisolone acetate</strong> (prednisolone) </td>
<td class="formItem">prednisolone acetate</td>
<td class="formItem">1.2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>boric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium bisulfite</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium citrate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68788-9876-5</td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA017100</td>
<td class="formItem">03/05/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Preferred Pharmaceuticals, Inc
							(791119022)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Preferred Pharmaceuticals, Inc</td>
<td class="formItem"></td>
<td class="formItem">791119022</td>
<td class="formItem">RELABEL(68788-9876)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>90fba723-51b1-4404-a30b-816f35001d91</div>
<div>Set id: 90fba723-51b1-4404-a30b-816f35001d91</div>
<div>Version: 1</div>
<div>Effective Time: 20120305</div>
</div>
</div> <div class="DistributorName">Preferred Pharmaceuticals, Inc</div></p>
</body></html>
